Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$62.56
+0.7%
$64.74
$52.50
$77.00
$1.36B0.55309,744 shs150,686 shs
BGM
Qilian International Holding Group
$13.50
-13.5%
$12.11
$5.26
$17.17
$1.31B1.3830,047 shs101,852 shs
Cryoport, Inc. stock logo
CYRX
Cryoport
$6.67
-3.3%
$6.07
$4.58
$10.37
$334.41M1.85530,709 shs589,576 shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$14.50
-2.9%
$16.87
$6.80
$25.29
$1.29B0.751.62 million shs1.58 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
+0.71%+0.97%+3.63%+0.11%-2.57%
BGM
Qilian International Holding Group
-13.52%+3.21%+16.88%+38.75%+1,349,999,900.00%
Cryoport, Inc. stock logo
CYRX
Cryoport
-3.33%-4.71%+3.09%+4.06%-37.02%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-2.95%-5.35%-31.25%-26.51%+97.55%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
4.2241 of 5 stars
3.51.00.03.32.53.31.3
BGM
Qilian International Holding Group
N/AN/AN/AN/AN/AN/AN/AN/A
Cryoport, Inc. stock logo
CYRX
Cryoport
3.484 of 5 stars
4.43.00.00.02.02.50.6
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.5344 of 5 stars
4.41.00.00.02.00.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
3.00
Buy$80.1328.08% Upside
BGM
Qilian International Holding Group
0.00
N/AN/AN/A
Cryoport, Inc. stock logo
CYRX
Cryoport
2.71
Moderate Buy$11.0064.92% Upside
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.87
Moderate Buy$32.14121.67% Upside

Current Analyst Ratings Breakdown

Latest CYRX, ANIP, TVTX, and BGM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$30.00
6/11/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$35.00 ➝ $32.00
5/16/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/16/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.00
5/12/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$86.00 ➝ $86.00
5/8/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/5/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $7.00
5/2/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.00
5/2/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$22.00 ➝ $23.00
4/23/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
4/21/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$62.00 ➝ $65.00
(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$674.07M2.01$6.93 per share9.03$21.13 per share2.96
BGM
Qilian International Holding Group
$25.10M52.29N/AN/A$6.10 per share2.21
Cryoport, Inc. stock logo
CYRX
Cryoport
$232.13M1.44$0.39 per share16.95$9.45 per share0.71
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$273.53M4.71N/AN/A$2.67 per share5.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$18.78M-$1.27N/A14.86N/A-1.28%15.87%6.88%8/5/2025 (Estimated)
BGM
Qilian International Holding Group
-$1.44MN/A0.00N/AN/AN/AN/AN/A
Cryoport, Inc. stock logo
CYRX
Cryoport
-$99.59M-$2.34N/AN/AN/A-70.08%-13.35%-6.43%8/5/2025 (Estimated)
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$111.40M-$2.81N/AN/AN/A-137.90%-1,636.87%-55.95%7/30/2025 (Estimated)

Latest CYRX, ANIP, TVTX, and BGM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$1.37$1.70+$0.33$0.69$179.75 million$197.12 million
5/7/2025Q1 2025
Cryoport, Inc. stock logo
CYRX
Cryoport
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
5/1/2025Q1 2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$0.55-$0.47+$0.08-$0.47$77.44 million$81.73 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
N/AN/AN/AN/AN/A
BGM
Qilian International Holding Group
N/AN/AN/AN/AN/A
Cryoport, Inc. stock logo
CYRX
Cryoport
N/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
1.52
2.74
1.97
BGM
Qilian International Holding Group
N/A
3.39
2.82
Cryoport, Inc. stock logo
CYRX
Cryoport
0.48
5.70
5.32
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
24.96
1.71
1.68

Institutional Ownership

CompanyInstitutional Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
76.05%
BGM
Qilian International Holding Group
N/A
Cryoport, Inc. stock logo
CYRX
Cryoport
92.90%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
12.70%
BGM
Qilian International Holding Group
58.66%
Cryoport, Inc. stock logo
CYRX
Cryoport
10.00%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
4.19%
CompanyEmployeesShares OutstandingFree FloatOptionable
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
60021.66 million18.36 millionOptionable
BGM
Qilian International Holding Group
29897.22 million2.48 millionN/A
Cryoport, Inc. stock logo
CYRX
Cryoport
1,02050.14 million44.44 millionOptionable
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
46088.81 million75.12 millionOptionable

Recent News About These Companies

Cantor Fitzgerald Comments on TVTX FY2026 Earnings
Travere Therapeutics, Inc. stock logo
Cantor Fitzgerald Predicts TVTX FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANI Pharmaceuticals stock logo

ANI Pharmaceuticals NASDAQ:ANIP

$62.56 +0.44 (+0.71%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$62.47 -0.09 (-0.14%)
As of 06/13/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Qilian International Holding Group NASDAQ:BGM

$13.50 -2.11 (-13.52%)
Closing price 06/13/2025 03:59 PM Eastern
Extended Trading
$13.75 +0.25 (+1.85%)
As of 06/13/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Cryoport stock logo

Cryoport NASDAQ:CYRX

$6.67 -0.23 (-3.33%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$6.66 0.00 (-0.07%)
As of 06/13/2025 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Travere Therapeutics stock logo

Travere Therapeutics NASDAQ:TVTX

$14.50 -0.44 (-2.95%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$14.50 +0.01 (+0.03%)
As of 06/13/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.